Survival outcomes associated with completion of adjuvant oxaliplatin-based chemotherapy for stage III colon cancer: a national population-based study
AuthorsBoyle, J. M.
Cowling, T. E.
van der Meulen, J.
Fearnhead, N. S.
Braun, Michael S
AffiliationDepartment of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK
MetadataShow full item record
AbstractThe impact of cycle completion rates of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer in real-world practice is unknown. We assessed its impact, and that of treatment modification, on 3-year cancer-specific mortality. 4147 patients with pathological stage III colon cancer undergoing major resection from 2014 to 2017 in the English National Health Service were included. Chemotherapy data came from linked national administrative datasets. Competing-risk regression analysis for 3-year cancer-specific mortality was performed according to completion of <6, 6-11, or 12 FOLFOX cycles, or < 4, 4-7, or 8 CAPOX cycles, adjusted for patient, tumour and hospital-level characteristics. Median age was 64 years. 32% of patients had at least one comorbidity. 42% of patients had T4 disease, and 40% N2 disease. Compared to completion of 12 FOLFOX cycles, cancer-specific mortality was higher in patients completing <6 cycles (sHR 2.17; 95% CI, 1.56 to 3.03) or 6-11 cycles (sHR 1.40; 95% CI, 1.09 to 1.78) (P < 0.001). Compared to completion of 8 CAPOX cycles, cancer-specific mortality was higher in patients completing <4 cycles (sHR 2.02; 95% CI 1.53 to 2.67) or 4-7 cycles (sHR 1.63; 95% CI 1.27 to 2.10) (P < 0.001). Dose reduction and early oxaliplatin discontinuation did not impact mortality in patients completing all cycles. Completion of all cycles of chemotherapy was associated with improved cancer-specific survival in real-world practice. Poor prognostic factors may have affected findings, however, patients completing <50% of cycles had poor outcomes. Clinicians may wish to facilitate completion with treatment modification in those able to tolerate it.
CitationBoyle JM, Kuryba A, Cowling TE, van der Meulen J, Fearnhead NS, Walker K, et al. Survival outcomes associated with completion of adjuvant oxaliplatin‐based chemotherapy for stage III colon cancer: A national population‐based study. Int J Cancer. 2021 Sep 28.
JournalInternational Journal of Cancer
- Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
- Authors: Schmoll HJ, Twelves C, Sun W, O'Connell MJ, Cartwright T, McKenna E, Saif M, Lee S, Yothers G, Haller D
- Issue date: 2014 Dec
- Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.
- Authors: André T, Meyerhardt J, Iveson T, Sobrero A, Yoshino T, Souglakos I, Grothey A, Niedzwiecki D, Saunders M, Labianca R, Yamanaka T, Boukovinas I, Vernerey D, Meyers J, Harkin A, Torri V, Oki E, Georgoulias V, Taieb J, Shields A, Shi Q
- Issue date: 2020 Dec
- Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
- Authors: Petrelli F, Labianca R, Zaniboni A, Lonardi S, Galli F, Rulli E, Rosati G, Corallo S, Ronzoni M, Cardellino GG, Mattioli R, Mambrini A, Ciuffreda L, Banzi M, Pusceddu V, Maiello E, Zampino M, Zagonel V, Marchetti P, Corsi D, Rimassa L, Cinieri S, Sobrero A
- Issue date: 2020 Apr 1
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
- Authors: Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, Meyerhardt JA, Vernerey D, Yamanaka T, Boukovinas I, Meyers JP, Renfro LA, Niedzwiecki D, Watanabe T, Torri V, Saunders M, Sargent DJ, Andre T, Iveson T
- Issue date: 2018 Mar 29
- Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study).
- Authors: Nakayama G, Takano N, Taniguchi H, Ishigure K, Yokoyama H, Teramoto H, Hashimoto R, Sakai M, Ishiyama A, Kinoshita T, Hayashi N, Nakamura M, Hattori N, Sato Y, Umeda S, Uehara K, Aiba T, Sonohara F, Hayashi M, Kanda M, Kobayashi D, Tanaka C, Yamada S, Koike M, Fujiwara M, Murotani K, Ando M, Ando Y, Muro K, Kodera Y
- Issue date: 2021 Feb